Daniel H. Albert

5.3k total citations
88 papers, 2.7k citations indexed

About

Daniel H. Albert is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Daniel H. Albert has authored 88 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 28 papers in Oncology and 20 papers in Hematology. Recurrent topics in Daniel H. Albert's work include Protein Degradation and Inhibitors (17 papers), Peptidase Inhibition and Analysis (10 papers) and Microtubule and mitosis dynamics (9 papers). Daniel H. Albert is often cited by papers focused on Protein Degradation and Inhibitors (17 papers), Peptidase Inhibition and Analysis (10 papers) and Microtubule and mitosis dynamics (9 papers). Daniel H. Albert collaborates with scholars based in United States, United Kingdom and Singapore. Daniel H. Albert's co-authors include Fred Snyder, James B. Summers, Steven K. Davidsen, Jennifer J. Bouska, Keith B. Glaser, Dee W. Brooks, Patrick Young, Randy L. Bell, Richard D. Dyer and Carl E. Anderson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniel H. Albert

84 papers receiving 2.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Daniel H. Albert	1.3k	582	498	313	277	88	2.7k
Mamoru Shoji	1.8k 1.4×	371 0.6×	493 1.0×	377 1.2×	360 1.3×	63	3.0k
Hiroyuki Miyachi	1.1k 0.8×	665 1.1×	340 0.7×	221 0.7×	171 0.6×	93	2.1k
Sumit Sahni	1.9k 1.4×	310 0.5×	1.1k 2.2×	273 0.9×	409 1.5×	90	3.6k
Maryanne Covington	912 0.7×	611 1.0×	585 1.2×	97 0.3×	355 1.3×	68	2.7k
Dennis Carney	1.7k 1.2×	262 0.5×	590 1.2×	451 1.4×	345 1.2×	51	3.4k
Philip Reigan	2.0k 1.5×	373 0.6×	677 1.4×	88 0.3×	364 1.3×	78	3.0k
Emmanuelle J. Meuillet	1.7k 1.2×	331 0.6×	334 0.7×	72 0.2×	244 0.9×	65	2.4k
Duane A. Burnett	728 0.5×	1.1k 1.9×	347 0.7×	113 0.4×	380 1.4×	108	2.6k
M. David Percival	1.4k 1.0×	638 1.1×	520 1.0×	72 0.2×	584 2.1×	68	3.1k
Anthony M. Treston	1.3k 1.0×	273 0.5×	532 1.1×	74 0.2×	371 1.3×	79	2.6k

Countries citing papers authored by Daniel H. Albert

Since Specialization

Citations

This map shows the geographic impact of Daniel H. Albert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel H. Albert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel H. Albert more than expected).

Fields of papers citing papers by Daniel H. Albert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel H. Albert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel H. Albert. The network helps show where Daniel H. Albert may publish in the future.

Co-authorship network of co-authors of Daniel H. Albert

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel H. Albert. A scholar is included among the top collaborators of Daniel H. Albert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel H. Albert. Daniel H. Albert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lam, Lloyd T., Xiaoyu Lin, Emily J. Faivre, et al.. (2017). Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors. Molecular Cancer Therapeutics. 16(8). 1511–1520. 55 indexed citations

Faivre, Emily J., Denise Wilcox, Xia Li, et al.. (2016). Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075. Molecular Cancer Research. 15(1). 35–44. 53 indexed citations

Lin, Xiaoyu, Xiaoli Huang, Tamar Uziel, et al.. (2016). HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues. Molecular Cancer Therapeutics. 16(2). 388–396. 45 indexed citations

Garcia‐Manero, Guillermo, Raoul Tibes, Tapan M. Kadia, et al.. (2015). Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational New Drugs. 33(4). 870–880. 20 indexed citations

Ji, Shundong, Yang Zhou, Martin J. Voorbach, et al.. (2013). Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrin αvβ3–Targeted Radiotracer 99mTc-3P-RGD2 99mTc-3P-RGD2: An Integrin αvβ3–Targeted Radiotracer to Monitor Linifanib Therapy. Journal of Pharmacology and Experimental Therapeutics. 346(2). 251–258. 18 indexed citations

Wang, Eunice S., Karen Yee, Liang Piu Koh, et al.. (2012). Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leukemia & lymphoma. 53(8). 1543–1551. 18 indexed citations

Mudd, Sarah R., Martin J. Voorbach, David R. Reuter, et al.. (2012). FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model. Cancer Chemotherapy and Pharmacology. 69(6). 1669–1672. 4 indexed citations

Jiang, Fang, Daniel H. Albert, Yanping Luo, et al.. (2011). ABT-869, a Multitargeted Receptor Tyrosine Kinase Inhibitor, Reduces Tumor Microvascularity and Improves Vascular Wall Integrity in Preclinical Tumor Models. Journal of Pharmacology and Experimental Therapeutics. 338(1). 134–142. 17 indexed citations

Frey, Robin R., Michael L. Curtin, Daniel H. Albert, et al.. (2008). 7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry. 51(13). 3777–3787. 42 indexed citations

10.

Jasinghe, Viraj J., Zhigang Xie, Jianbiao Zhou, et al.. (2008). ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. Journal of Hepatology. 49(6). 985–997. 31 indexed citations

11.

Dai, Yujia, Niru B. Soni, Lori J. Pease, et al.. (2007). Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(1). 386–390. 31 indexed citations

12.

Ji, Zhiqin, Asma A. Ahmed, Daniel H. Albert, et al.. (2006). Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 16(16). 4326–4330. 17 indexed citations

13.

Li, Junling, Lori J. Pease, Paul Tapang, et al.. (2005). ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia. Cancer Research. 65. 1407–1407.

14.

Glaser, Keith B., et al.. (2003). Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA. Biochemical and Biophysical Research Communications. 310(2). 529–536. 181 indexed citations

15.

Dai, Yujia, Yan Guo, Jun Guo, et al.. (2003). Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorganic & Medicinal Chemistry Letters. 13(11). 1897–1901. 34 indexed citations

16.

Marcotte, Patrick A., Zhiwen Guan, Terrance J. Magoc, et al.. (1999). Evaluation of the Inhibition of other Metalloproteinases by Matrix Metalloproteinase Inhibitors. Journal of enzyme inhibition. 14(6). 425–435. 6 indexed citations

17.

Albert, Daniel H., Richard G. Conway, Terrance J. Magoc, et al.. (1996). Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.. Journal of Pharmacology and Experimental Therapeutics. 277(3). 1595–1606. 5 indexed citations

18.

Albert, Daniel H., Terrance J. Magoc, Hollis D. Kleinert, et al.. (1996). Ex Vivo Inhibition of PAF-Induced β-Thromboglobulin Release in Man by ABT-299, a Potent PAF Antagonist. Advances in experimental medicine and biology. 416. 381–387. 1 indexed citations

19.

Summers, James B., Daniel H. Albert, James H. Holms, et al.. (1994). N-(Acyloxyalkyl)pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist. Journal of Medicinal Chemistry. 37(26). 4423–4429. 39 indexed citations

20.

Soupart, Pierre, et al.. (1979). Accumulation, Nature, and Possible Functions of the Malachite Green Affinity Material in Ejaculated Human Spermatozoa. Fertility and Sterility. 32(4). 450–454. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact